Clinical trials: Eye Allergies
Allergic Conjunctivitis
Safety Study for Bepotastine Besilate Ophthalmic Solution in Normal Volunteers
Safety study for bepotastine besilate ophthalmic solution in normal volunteers
- Trial name
- NCT00586625
- Testing
- Bepreve
- Volunteers
- 861 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Allergic Conjunctivitis
Assessment of Alcon's Ocular Image Quantification System
The purpose of this study was to evaluate ocular responses with different allergen provocation methods.
- Trial name
- NCT01282138
- Testing
- Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol), Dextran 70 0.1%, hydroxypropyl methylcellulose 0.3% (Tears Naturale II)
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Alcon Research
Allergic Conjunctivitis
Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients
The objective of this study is to further evaluate the safety of Olopatadine Ophthalmic Solution 0.1% in Japanese children with allergic conjunctivitis.
- Trial name
- NCT01109485
- Testing
- Olopatadine hydrochloride ophthalmic solution 0.1%
- Where
- Japan
- Volunteers
- 42 people
- Sponsor
- Alcon Research
Allergic Conjunctivitis
Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis
To evaluate the efficacy and safety of two concentrations of PRT-2761 as a topical ophthalmic solution for the treatment of the signs and symptoms of acute and chronic allergic conjunctivitis.
- Trial name
- NCT03320434
- Testing
- PRT-2761 0.5%, PRT-2761 1%, Patanol
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- ORA, Inc.
Allergic Conjunctivitis
Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis
The purpose of this study is to evaluate patient perceptions of olopatadine 0.2% dosed once daily in patients previously treated with twice-daily, topical, ocular, anti-allergy medications.
- Trial name
- NCT01159769
- Testing
- Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)
- Volunteers
- 215 people
- Sponsor
- Alcon Research
Cataract, Lens Opacities
PMCF Retrospective Study Outcomes of a Premium Monofocal IOL
Multicentric, retro- / prospective, open-label, observational PMCF study to investigate visual performance, contrast sensitivity and patient satisfaction after mono- or bilateral implantation of Isopure 1.2.3.
- Trial name
- PHY2110 (NCT04874376)
- Testing
- IOL implantation experimental (Isopure 1.2.3.)
- Where
- 6 sites in Spain
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Beaver-Visitec International, Inc.
Diabetes Mellitus - Type 1, Diabetes Mellitus - Type 2
Diabetes Visual Function Supplement Study
This study will evaluate the effects of a novel multi-component dietary supplement on the visual function and retinal structure of patients with diabetes with both no diabetic retinopathy and mild to moderate diabetic…
- Conditions
- Diabetes Mellitus - Type 1, Diabetes Mellitus - Type 2, Non-proliferative Diabetic Retinopathy
- Trial name
- DiVFuSS (NCT01646047)
- Testing
- multi-component nutritional supplement capsules, multi-component dietary supplement
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- ZeaVision, LLC
Lymphoma
Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)
To understand the safety and efficacy of Revlimid® Capsules 2.5 mg and 5 mg (hereinafter referred to as Revlimid) under actual conditions of use in patients with relapsed or refractory adult T-cell leukemia lymphoma (hereinafter…
- Trial name
- NCT03098589
- Testing
- Revlimid
- Where
- Japan
- Volunteers
- 1,149 people
- Sponsor
- Celgene
Conjunctivitis, Allergic
AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis
This study will evaluate the safety and efficacy of AGN-229666 for the treatment of seasonal or perennial allergic conjunctivitis.
- Trial name
- NCT02082262
- Testing
- AGN-229666
- Where
- Japan
- Volunteers
- 140 people
- Sponsor
- Allergan
Seasonal Allergic Rhinitis, Hay Fever
Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR
Evaluate the relative efficacy of four dosing regimens of bilastine tablets (given either once or twice per day) versus placebo in patients with Seasonal Allergic Rhinitis (SAR) in the Mountain Cedar season in south Texas and…
- Conditions
- Seasonal Allergic Rhinitis, Hay Fever, Allergic Conjunctivitis, Hypersensitivity
- Trial name
- NCT00574379
- Testing
- Bilastine
- Where
- 13 sites in United States
- Volunteers
- 805 people
- Sponsor
- Faes Farma, S.A.
Dry Eye
A 2-week Clinical Comparison of SYSTANE® Ultra to Sensitive Eyes Rewetting Drops in Contact Lens Wearing Patients.
To evaluate safety with the use of Systane Ultra in contact lens wearers. A comparison to a currently marketed contact lens rewetting drop will be included as a control.
- Trial name
- NCT00769665
- Testing
- Systane Ultra, Sensitive Eyes Rewetting Drops
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Allergic Conjunctivitis
A Study of TL-925 for the Treatment of Allergic Conjunctivitis
In this prospective Phase 2, single-center, randomized, double-masked, placebo-controlled study, approximately 70 subjects with allergic conjunctivitis will be randomized 1:1 to receive either TL-925 or placebo as topical…
- Trial name
- NCT06153342
- Testing
- TL-925
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Telios Pharma, Inc.
Allergic Conjunctivitis
A Study Of The Safety And Effectiveness Of A New Treatment For Allergic Conjunctivitis
This study will evaluate the safety and efficacy of a new allergy medication
- Trial name
- NCT00375596
- Testing
- Ketotifen/vasoconstrictor
- Sponsor
- Bausch & Lomb Incorporated
Allergic Conjunctivitis
Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution
To compare the safety and tolerability of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% combination ophthalmic solution versus its vehicle in healthy adult subjects and in pediatric subjects.
- Trial name
- NCT05815758
- Testing
- Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo), Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution
- Where
- 7 sites in United States
- Volunteers
- 512 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Allergic Rhinitis, Allergic Conjunctivitis
Demonstration of Equivalence and Early Onset of a Novel Anti-allergic Nasal Spray Compared to Marketed Nasal Spray
Intranasal corticosteroids are accepted as safe and effective first-line therapy for allergic rhinitis, especially in treatment of persistent symptoms.
- Conditions
- Allergic Rhinitis, Allergic Conjunctivitis, Hayfever
- Trial name
- NCT03755557
- Testing
- Rhinocort, Budesolv
- Where
- Austria
- Volunteers
- 82 people
- Sponsor
- Marinomed Biotech AG
Allergic Conjunctivitis
AGN-229666 for the Treatment of Allergic Conjunctivitis
This study will evaluate the safety and efficacy of AGN-229666 for the treatment of allergic conjunctivitis.
- Trial name
- NCT01754766
- Testing
- AGN-229666, vehicle of AGN-229666
- Where
- Japan
- Volunteers
- 90 people
- Sponsor
- Allergan
Corneal Sensation Reduced, Corneal Dystrophy
Defining the Operating Parameters for a Rebound-esthesiometer
The purpose of this study is to define the operating parameters for a new method to measure corneal sensitivity.
- Conditions
- Corneal Sensation Reduced, Corneal Dystrophy, Corneal Degeneration, Corneal Transplant Failure
- Trial name
- NCT04384094
- Testing
- Esthesiometer measurement
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Icare Finland Oy
Allergic Conjunctivitis
A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC)
The purpose of this study is to evaluate the safety, efficacy, and dose response of brimonidine tartrate ophthalmic solution as compared to placebo in the prevention of allergen-induced conjunctival redness using a conjunctival…
- Trial name
- NCT01275105
- Testing
- Vehicle, Brimonidine Tartrate 0.01%, Brimonidine Tartrate 0.025%
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Eye Therapies, LLC
Vernal Keratoconjunctivitis
Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis
The objective of this study is to compare the efficacy of two different dosing regimen of NOVA22007 (1mg/ml ciclosporin/cyclosporine) eye drops, emulsion versus placebo (vehicle of the formulation) administered four times a day…
- Trial name
- NCT01751126
- Testing
- NOVA22007 ''Ciclosporin''
- Where
- 46 sites in United States, Croatia and 9 more
- Volunteers
- 169 people
- Sponsor
- Santen SAS
Age Related Macular Degeneration
Sensitivity and Specificity of the Home Macular Perimeter (HMP)
The primary objective of this study is to estimate the sensitivity of the HMP test in identifying visual field functional defects in subjects with CNV secondary to AMD, and differentiate them from intermediate AMD subjects.
- Trial name
- HMP (NCT00595998)
- Where
- Israel
- Volunteers
- 42 people
- Sponsor
- Notal Vision Ltd.